Ms. Goonewardene is currently Vice Chancellor for Innovation & Strategic Investment at the University of Texas System (UTS), AMA Board, MBI Board and US Commerce Advisor. In addition, Julie has a track record as an experienced entrepreneur, having co-founded and served as President and CEO of Cantilever Technologies, a venture-backed software company that was successfully acquired. Cantilever’s customers were Fortune 500 companies. Prior to Cantilever, she was President of the Strategic Systems Group (SSG), a boutique information technology consulting firm, and co-founder of Technology Solutions (TSC), a professional IT services firm which went public three years after its inception. In addition to her role at UTS, Ms. Goonewardene is an author, frequent speaker and consultant on entrepreneurship and innovation. Based on success in these areas, Julie was elected to the Board of Trustees for the American Medical Association (AMA), the Board of Directors of the Personalized Medicine Coalition and Matrix-Bio and is an advisor on the National Advisory Council on Innovation and Entrepreneurship (NACIE) Board to the US Commerce Secretary. As a first generation American born to Sri Lankan and Australian parents, she brings a unique global perspective to her endeavours.
Peter KeelingChief Executive Officer
As Chief Executive Officer of Diaceutics, Peter has driven the organization from its inception in 2005 to become a leader in innovative solutions that enable pharma to leverage diagnostic testing globally. He has overseen the expansion and development of Diaceutics to support pharma therapy and diagnostic commercialization via a worldwide team.
Peter recognised early on that precision medicine would be an increasingly large part of the drug development paradigm, representing a shift in how the pharmaceutical industry operates. Today, he is a thought leader in precision medicine commercialization and Diaceutics provides the top 20 precision medicine pharma companies with the data, analytics and global lab implementation services required to align biomarker and diagnostic demand with therapy, patient and revenue targets in key markets.
Peter’s role with Diaceutics complements over thirty years’ experience in international healthcare which began at GSK and Diagnology. He has operated and led companies and teams in the US, Europe, Asia and BRIC countries, inspiring product innovation and global launches while repeatedly delivering high corporate value growth for shareholders.
Peter has spent two extended periods in applied industrial research, including a year at MIT’s Pharmaceutical Program at the Sloan School of Management in Boston. He has also published widely and is a respected speaker at precision medicine events around the world.
Ryan KeelingChief Operating Officer
As Chief Operating Officer of Diaceutics, Ryan is responsible for overseeing operations across the company.
Ryan joined Diaceutics in 2009 and has utilised his expertise in commercial, data and pharma strategy to work on multiple diagnostic/therapy launches since then. Ryan is focused on providing strategic advice to our pharma clients that is supported with a strong background in market access and reimbursement.
Philip WhiteChief Financial Officer
As Chief Financial Officer of Diaceutics, Philip has responsibility for all administrative, financial and risk management operations. He works closely with the management team and Board of Directors to develop and implement strategies across the organization. In addition, Philip is responsible for maintaining compliance with US, UK and Republic of Ireland financial reporting, taxation and corporate governance standards.
Philip has over ten years’ financial and management experience as the Finance Director of a company in a global export market, as well as significant experience in product development, planning and product launch. He is an acting board member of a UK charity and has significant experience at board level in the charitable and not-for-profit sector. He is a member of the Institute of Chartered Accountants in Ireland, an associate member of the Institute of Taxation and a member of the Institute of Directors.
Jordan Clark, PhDManaging Director
As a Managing Director of Diaceutics, Jordan leads the client projects to ensure the Diaceutics Method® is harnessed to deliver maximum strategic and critical thinking, and leverage the diagnostic in support of targeted therapies. He has worked on over 20 targeted therapies, optimizing diagnostics into a supportive environment for precision medicine.
Jordan has academic and professional qualifications in biomedical and clinical sciences. He is a state licensed scientist in hematology, spending five years at Cambridge University diagnosing cancer patients and working to aid their care. Jordan is renowned for biomarker testing through his role at UK NEQAS, one of the largest proficiency test providers, where he founded seven new quality programs, including the first for FLT3 and NPM1, which involved engaging with 200 AML diagnostic laboratories globally.
Sanna JousiHead of Marketing
As Head of Marketing for Diaceutics, Sanna is responsible for the development and execution of the marketing strategy. Previously in her role as a Managing Director, she led a partnership with Omnicom advertising agency and developed an agency dedicated to unlocking the power of precision medicine communication.
Sanna has also driven the development of digital products and interactive multimedia software solutions built on the Diaceutics Method® to support diagnostic and precision therapy launch.
Prior to her promotion to Managing Director in 2012, Sanna was Vice President of Research and Development for Diaceutics, using her experience in incorporating multimedia solutions as part of corporate training to build the Diaceutics Method® into an interactive software tool. She is the founder and former Managing Director of SLP Innovations Ltd., which organized, coordinated and delivered tailor-made training to key biotechnology companies in Finland.
Steve VitaleManaging Director
As a Managing Director of Diaceutics, Steve is responsible for leading client engagements, providing clear and actionable insights based on robust data related to the development and commercialization of companion diagnostics paired with targeted therapies.
Steve’s experience in the pharmaceutical industry includes a 12 year tenure at GlaxoSmithKline, where he supported and led US market launches of multiple brands and indications across a variety of therapeutic areas. As Director of Global Marketing, he oversaw international efforts to drive market development and lifecycle activities for the metabolic product portfolio, and spearheaded the creation of the innovation function within the US vaccines division. In addition, Steve has served as Management Advisor for TGaS Advisors, building the global marketing benchmark solution from its infancy into a standard offering for the firm.